A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy.

ABSTRACT: MicroRNAs are now increasingly recognized as biomarkers of disease progression. Several quantitative real-time PCR (qPCR) platforms have been developed to determine the relative levels of microRNAs in biological fluids. We systematically compared the detection of cellular and circulating microRNA using a standard 96-well platform, a high-content microfluidics platform and two ultra-high content platforms. We used extensive analytical tools to compute inter- and intra-run variability and concordance measured using fidelity scoring, coefficient of variation and cluster analysis. We carried out unprejudiced next generation sequencing to identify a microRNA signature for Diabetic Retinopathy (DR) and systematically assessed the validation of this signature on clinical samples using each of the

SUBMITTER: Farr RJ 

PROVIDER: S-EPMC4649912 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature